Akari Therapeutics Plc Stock Piotroski F Score
AKTX Stock | USD 1.19 0.02 1.65% |
Akari | Piotroski F Score |
At this time, it appears that Akari Therapeutics' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Unavailable
Current Return On Assets | Negative | Focus |
Change in Return on Assets | Decreased | Focus |
Cash Flow Return on Assets | Negative | Focus |
Current Quality of Earnings (accrual) | Decreasing | Focus |
Asset Turnover Growth | No Change | Focus |
Current Ratio Change | Decrease | Focus |
Long Term Debt Over Assets Change | N/A | Focus |
Change In Outstending Shares | Decrease | Focus |
Change in Gross Margin | No Change | Focus |
Akari Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Akari Therapeutics is to make sure Akari is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Akari Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Akari Therapeutics' financial numbers are properly reported.
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Total Current Liabilities | 7.9 M | 4.6 M |
|
| |||||
Non Current Liabilities Total | 1.1 M | 1.1 M |
|
| |||||
Total Assets | 4.1 M | 4.4 M |
|
| |||||
Total Current Assets | 4.1 M | 4.3 M |
|
|
Akari Therapeutics PLC F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Akari Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Akari Therapeutics in a much-optimized way.
-0.34 | 0.37 | 0.21 | 0.36 | 0.36 | -0.53 | ||
-0.34 | -0.89 | 0.25 | -0.99 | -0.99 | 0.28 | ||
0.37 | -0.89 | -0.17 | 0.88 | 0.88 | -0.34 | ||
0.21 | 0.25 | -0.17 | -0.23 | -0.23 | -0.09 | ||
0.36 | -0.99 | 0.88 | -0.23 | 1.0 | -0.32 | ||
0.36 | -0.99 | 0.88 | -0.23 | 1.0 | -0.32 | ||
-0.53 | 0.28 | -0.34 | -0.09 | -0.32 | -0.32 |
Click cells to compare fundamentals
About Akari Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
About Akari Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akari Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akari Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akari Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Akari Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akari Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akari Stock
0.62 | EFTR | Effector Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Akari Stock
0.82 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
0.78 | NRSNW | NeuroSense Therapeutics | PairCorr |
0.77 | ACB | Aurora Cannabis Trending | PairCorr |
0.73 | CGC | Canopy Growth Corp Trending | PairCorr |
0.71 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Akari Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akari Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akari Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akari Therapeutics PLC to buy it.
The correlation of Akari Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akari Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akari Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akari Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Akari Therapeutics Altman Z Score, Akari Therapeutics Correlation, Akari Therapeutics Valuation, as well as analyze Akari Therapeutics Alpha and Beta and Akari Therapeutics Hype Analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Akari Stock analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Stocks Directory Find actively traded stocks across global markets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Akari Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akari Therapeutics. If investors know Akari will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akari Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Return On Assets (1.16) | Return On Equity (12.81) |
The market value of Akari Therapeutics PLC is measured differently than its book value, which is the value of Akari that is recorded on the company's balance sheet. Investors also form their own opinion of Akari Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akari Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akari Therapeutics' market value can be influenced by many factors that don't directly affect Akari Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akari Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akari Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akari Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.